185 related articles for article (PubMed ID: 32084002)
1. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
Ballestrero A; Cirmena G; Dominietto A; Garuti A; Rocco I; Cea M; Moran E; Nencioni A; Miglino M; Raiola AM; Bacigalupo A; Patrone F
Int J Lab Hematol; 2010 Aug; 32(4):387-91. PubMed ID: 19968720
[TBL] [Abstract][Full Text] [Related]
3. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
4. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
7. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
8. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Akard LP; Cortes JE; Albitar M; Goldberg SL; Warsi G; Wetzler M; Ericson SG; Radich JP
Arch Pathol Lab Med; 2014 Sep; 138(9):1186-92. PubMed ID: 24308645
[TBL] [Abstract][Full Text] [Related]
9. Detection of
Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
[TBL] [Abstract][Full Text] [Related]
10. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
[TBL] [Abstract][Full Text] [Related]
12. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
13. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
Lee YK; Lee DW; Kim YL; Lee S; Min CK; Kim YJ; Oh IH; Kim TG; Kim CC; Kim DW
Int J Hematol; 2002 Aug; 76(2):180-5. PubMed ID: 12215018
[TBL] [Abstract][Full Text] [Related]
14. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
[TBL] [Abstract][Full Text] [Related]
16. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
